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Discussion
These results confirm the presence of chloroquine-resistant
p. falciparum in the eastern Transvaal. No information is,
however, available concerning the in vivo response of the
same parasites to chloroquine. There was a wide range of
susceptibility to sulphadoxine/pyrimethamine (MICs ranged
from 0,2 to 60 J,lmoVI). The isolates fell into two distinct
groups, those with MICs < 1 J,lmoVI and those with MICs
~ 20 J,lmol/l. It was not possible to draw conclusions
regarding the Fansidar resistance status of these isolates as
the discriminatory MIC values for resistant isolates in the
WHO sUlphadoxine/pyrimethainine in vitro test have not yet
been determined. Various authors have found that resistant
and sensitive isolates can easily be distinguished by their
MICs"" and it is therefore possible that 2 isolates in this study
with MICs ~ 20 I1moVI may in fact be resistant to Fansidar.
Since all the cases were classified as local transmission by
the authorities, the results indicate that there is transmission
of chloroquine-resistant and possibly Fansidar-resistant P.
falciparum malaria in this region. These data are considered
important to the planning of malaria control strategies for the
area. Continued monitoring of the susceptibility to Fansidar
(both in vivo and in vitro) should be seen as a priority.
Immunity to malaria is known to shorten the duration of
individuarinfections and to enhance the effect of antimalarial
drugs!' Chloroquine may still have a role to play in malaria
control but resistance to this drug would pose a threat to
non-immune tourists travelling to this area.
As outlined earlier, chloroquine-resistant P. falciparum is
widespread in southern Africa. A large number of our malaria
cases are imported into the country (> 30%) (Department of
National Health and Population Development - notification
data) and it is therefore not surprising that chloroquine
resistance should be detected in our malarious areas.
Currently, the eastern Transvaal is still documented as a low-
risk area where chloroquine alone or no prophylaxis is
recommended.22 We believe that the eastern Transvaal
should be reclassified as a moderate to high-risk area
(mainly from November to May) where prophylaxis such as
chloroquine plus proguanil or mefloquine or doxycycline
should be recommended to tourists.
This study will continue in the next malaria season.
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Antimalarial measures -
type, sources of advice and
compliance among tourists
to Natal/KwaZulu
G. B. Wilken, L. Baker
Typical advice on antimalarial measures provided by
pharmacies as well as actual behaviour in this regard and
sources of advice accessed by tourists to northern Natal/
Kwazulu were canvassed by telephonic interviews with 70
pharmacies and 53 'care providers' (members of travel
parties). Doctors (26%) and phannacists (40%) were the
most commonly approached sources of antimalarial
advice. Professional recommendations frequently involved
chloroquine-based drugs (80% of recommended drugs),
despite the chloroqUine-resistant status of the study area.
Drug choice reflected the limited availability of new
alternatives to chloroquine at the time the study was
conducted, as well as ignorance of drug resistance in the
area Possible reasons for the inappropriate nature of many
of the reported recommendations, as well as an approach
to the dissemination of future prophylactic policy
documents, are discussed.
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Increased travel to areas where malaria is endemic, drug
resistance and, until recently, the unavailability of certain
drugs in South Africa have hampered the provision of sound,
uncomplicated and unconflicting advice on prophylaxis,
despite the adequacy of current prophylaxis policy.' This
study describes typical advice on antimalarial measures
provided to the public, and the prophylaxis used by tourists
to northern Natal/Kwazulu, an area of known chloroquine
resistance!-S Since data collection preceded the release of.
proguanil and met/oquine, the results do not accurately
reflect current antimalarial behaviour, but they do provide a
basis from which to document further changes in
prophylactic advice and usage. The results are being used in
the design of a surveillance system investigating use of
antimalarial prophylaxis and the activities of tourists who
contract malaria, aimed at providing continually updated
data useful for policy formulation and the targeting of
education.
Methodology
Information was acquired in two ways. Pharmaceutical
advice was canvassed by telephoning 39 Durban and 31
Johannesburg pharmacies. Respondents were randomly
selected (every 20th listing) from the South African
Pharmacy Council's Registry of Pharmacies for the Republic
of South Africa (1992). The interviewer asked to speak to
someone concerning malaria prevention. Posing as a person
making enquiries on behalf of a group, including a pregnant
woman and a 2-year-old child, visiting Ndumo Game
Reserve, typical advice for these categories was obtained.
Actual behaviour of tourists with regard to antimalarial
measures was assessed with the co-operation of the
Kwazulu Bureau of Natural Resources (KBNR), which made
its booking register available. Thirty telephonic interviews
with travel party members who considered themselves the
group's 'care providers' from Natal and 23 from the
Transvaal were conducted. Respondents in this category
had visited northern Natal/Kwazulu during summer and
were randomly selected for interview. Only visitors to Kosi
Bay, Ndumo Game Reserve and Tembe Elephant Reserve
were interviewed, since these more northern reserves are
most likely to be perceived by both tourists and pharmacists
as posing a higher risk from malaria than the KBNR's more
southerly regions. The diversity of accommodation and
activities available in these reserves provide a sample
reasonably representative of tourists to this region.
Compliance, drug type and sources of advice were
documented. Use of personal barrier protection was also
recorded.
Results and discussion
Pharmaceutical advice was canvassed because of the high
number of tourists who reported having used pharmacies as
a source of advice, as well as for reasons of convenient
access. While much of the reported advice is dubious and
ignored the resistant status of the area, we stress that any
criticism is equally applicable to advice stemming from
medical sources, as evinced by reported behaviour based
on a doctor's advice (see Table 11).
Table I lists the prophylactic regimens suggested by 70
pharmacies and indicates heavy reliance on chloroquine-
based drJgs for a chloroquine-resistant area (currently
requiring mefloquine or proguanil + chloroquine or
doxycycline). Although at the time of going to press
mefloquine and proguanil had only recently been sanctioned
for release (or re-release in the case of proguanil) by the
Medicines Control Council and were still difficult to obtain,
the low number of recommendations to use Maloprim, or
combinations of chloroquine-based drugs and Maloprim,
suggests that availability has less influence on advice
offered than perceived risk or ignorance of chloroquine
resistance in the area. Maloprim, alone or in combination_
with chloroquine, was at that stage the only readily available
alternative to chloroquine. Children in particular were offered
chloroquine (94%), mostly as Daraclor (pyrimethamine +
chloroquine) tablets or syrup (80%). Suggested drugs for
use in pregnancy included Maloprim/Maloprim + folic acid
(51 % of drugs recommended), although the same agencies
recommended chloroquine-based drugs for adults and
children. Given the usefulness of chloroquine in pregnancy
this begs explanation, especially since the high number of
referrals and suggestions that pregnant women do not enter
malarious areas suggest comprehension of the·risks malaria
poses to the fetus. There seems to be some confusion
about the need for folic acid supplementation with various
prophylactic regimens - it is in fact only required when
drugs which interfere with the metabolism of folic acid are
used during pregnancy. Pyrimethamine and proguanil are
folic acid antagonists which may affect its metabolism, and
since folic acid requirements increase during pregnancy,
supplementation with either folic or folinic acid is necessary.
The use of chloroquine in isolation does not necessitate folic
acid supplementation..
Two of the pharmacies whose suggestions include
Maloprim (pyrimethamine + dapsone) made enquiries about
sulphone sensitivity. Regimens were adjusted for size/weight
Table I. Prophylactic advice provided by 70 pharmacies
Advice Adults Pregnant women Children
Daraclor 39 (9) 4 56
+ folate 3
Nivoquine 9 (1) 3 7
+ folate 2
Nivoquine + Maloprim 9 (1)
+ folate 1













( ) = No_ of cases where suggested regimen deviated from the manufacturers'.
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in only 2 instances. Only 3 pharmacies suggested further
consultation with sources of advice other than medical
practitioners and gynaecologists.
Barrier protection methods were recommended as
follows: none (45), bed nets (3), repellant coils or pads (6),
repellant creams and sprays (22), protective clothing (3).
The advice was solicited by asking, 'Is there anything else
you can tell me?' at the conclusion of each interview. The
regional variation in emphasis on barrier protection (77% of
the Transvaal group did not recommend these precautions,
as opposed to only 54% in the Natal group) remains
unexplained.
Tourists' drug choice, compliance, source of advice and
adverse reactions are listed in Table 11. Chloroquine-based
drugs were used in isolation or combined with pyrimetha-
mine by 71 % of respondents. Maloprim and proguanil, in
isolation or with chloroquine, were used by only 29% of
respondents who took some sort of prophylaxis. Twenty-six
per cent of reported prophylactic practice was based on a
doctor's advice and 40% on advice from a pharmacist.
The use of personal barrier protection and the reasons for
use/non-use are set out in Table Ill. Twenty-three of the 54
respondents did not use personal barrier protection. Of the
31 who did use some form of protection, 42% did so solely
with malaria in mind; 29% employed barrier methods simply
to avoid being bitten, and 29% with a view to malaria
prevention as well as irisect avoidance. All respondents who
did not resort to personal barrier protection reported that
they did not use it because they were not bothered by
insects. It seems that the presence of 'nuisance' mosquitoes
or other insects promotes the use of barrier methods.
Increased travel to malarious areas of differing resistance
status, seasonality and prevalence of Plasmodium species
make the provision of advice on prophylaxis difficult. Within
our borders the situation is confounded by the spread of
chloroquine-resistant P falciparum, as well as the
occurrence of P ovale.' These factors necessitate recourse
to more toxic or less well-known drugs, and provision of
increasingly individual and specific advice to travellers.
Ideally, any antimalarial strategy should be simple, so that
advice can be given confidently by non-specialists and
adopted easily by travellers.' Complicated regimens result in
poor compliance, as does conflicting or confusing advice·
The formulation of good prophylactic regimens in South
Africa has been impeded by poor drug availability, resulting
in lack of familiarity with newly available drugs and
combinations of these and more familiar compounds. A
sensible approach' is to classify advice requirements into
'specialist' and 'routine'. This would allow specific targeting
of medical education and information, so that practitioners
and pharmacists can confidently handle routine enquiries
and refer requests for specialist advice to appropriate
centres of expertise. The latter group would be charged with
advising travellers to areas of high drug resistance, those at
special exposure risk or at high risk from malaria, those for
whom routine measures are contraindicated, and long-stay
residents.
Underlying reasons for the inappropriate advice reported
include a history of limited drug availability, political
restrictions on travel destinations, low perceived risk, lack of
clarity and contradictory accounts of the extent of
chloroquine resistance within South African malarious areas.
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Table Ill. Barrier protection and reasons for use and non-use
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For example, reports of chloroquine-resistance from the
Transvaal,s,s-" the chloroquine-resistant status of all
malarious areas adjacent to the Transvaal, and the high
number of imported cases reported from within this region
are to some extent at odds with the current consensus
document,' which recommends chloroquine alone for this
region. Adding further confusion to the resistance scenario,
northern NataVKwazulu is described as an area of low-level
chloroquine resistance,'2 despite studies documenting a high
prevalence of strongly resistant malaria.3,4
It is likely that the high incidence of malaria reported for
the 1992/93 season:"o together with extensive coverage in
both the medical and the popular press, will have increased
awareness of newly available and necessary drugs on the
part of both travellers and medical advisors. Since all the
recommended drugs in the otherwise sound and widely
distributed TPS Drug Information Centre/National Health
malaria prophylaxis document' are now available, we look
forward to documenting reliance on more appropriate
drugs or drug combinations, Ongoing medical ediJcation
for doctors and pharmacists is vital for sound provision of
advice in a changeable setting, especially given recently
gazetted changes to the Pharmacy Act (Government
Gazette 25 June 1993) which will increase opportunities
for the involvement of pharmacists in primary health care
and health education, The sizeable role the travel industry
plays in providing information on prophylaxis has been
documented8 and travel agents must be kept aware of
current policy, not only through opportunistic use of ~ravel
conferences but also through formal channels. Future
antimalaria documentation intended for providers of
advice on prophylaxis should list, and encourage
consultation with, existing centres of expertise.
We thank the Kwazulu Bureau of Natural Resources for
their assistance and all the respondents; who gave so
generously of their time.
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Assessment of age-related
bone loss in normal South
African women by means
of the Hologic QDR 1000
system
A. A. Kalla, A. B. Fataar, L. Bewerunge
The aim of this study was to evaluate age-related changes
in cortical and trabecular bone mineral density (BMD) in
South African subjects, and to develop a local reference
database for dual energy X-ray absorptiometry with tl}e
QDR 1000 densitometer. A questionnaire was used t~.'
recruit volunteers. Age, years since menopause, use of
medications and medical diseases were recorded. Me,ri
were excluded. Only whites and coloureds were studied.
Three hundred and eleven women had single
measurements over a 2-year period. Seven sets of
subjects were defined according to age (18 - 44; 45 - 49;
50 - 54; 55 - 59; 60 - 64; 65 - 69; > 70 years) (N =163; 32;
35; 23; 25; 16; 17 respectively). Height and weight did not .
change significantly with age. There were significant
differences in lumbar and femoral BMD (Ward's) compared
with those of American subjects in the different age
categories. Both the lumbar and total femoral BMD began
to fall significantly between the ages of 60 and 65 years (P
< 0,01). Ward's triangle showed a significant fall in BMD
between 45 and 50 years of age (P < 0,01). Ward's BMD
predicted 36% of the variation in lumbar BMD at 45 years
but 10% at 70 years. Ward's triangle is a useful predictor
of femoral bone loss in later years. The fracture threshold
at the lumbar vertebrae was 0,822 g/cm2; at Ward's
triangle it was 0,443 g/cm2. This gave a 16% prevalence of
osteopenia in the lumbar region and a prevalence of 24%
at Ward's area.
S Air Med J 1994; 84: 398-404.
Osteoporosis is a major cause of morbidity and mortality
among elderly women in the UK, USA and Europe.,,2
Numerous risk factors for osteoporotic fracture have been
defined, but they have poor predictive value in assessing an
individual's susceptibility to fracture. 3 Bone mineral density
(BMD) measurement is the only definitive way of predicting
fracture risk.' Studies in South Africa are lacking, but there is
evidence that, among some groups of people, the
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Nuclear Medicine, Groote Schuur Hospital and University of Cape Town
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